The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Interactions between antidepressants and P‐glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings
Open accessAbstract
The drug efflux pump P‐glycoprotein (P‐gp) plays an important role in the function of the blood–brain barrier by selectively extruding certain endogenous and exogenous molecules, thus limiting the ability of its substrates to reach the brain. Emerging evidence suggests that P‐gp may restrict the uptake of several antidepressants into the brain, thus contributing to the poor success rate of current antidepressant therapies. Despite some inconsistency in the literature, clinical investigations of potential associations between functional single nucleotide polymorphisms in ABCB1, the gene which encodes P‐gp, and antidepressant response have highlighted a potential link between P‐gp function and treatment‐resistant depression (TRD). Therefore, co‐administration of P‐gp inhibitors with antidepressants to patients who are refractory to antidepressant therapy may represent a novel therapeutic approach in the management of TRD. Furthermore, certain antidepressants inhibit P‐gp in vitro, and it has been hypothesized that inhibition of P‐gp by such antidepressant drugs may play a role in their therapeutic action. The present review summarizes the available in vitro,in vivo and clinical data pertaining to interactions between antidepressant drugs and P‐gp, and discusses the potential relevance of these interactions in the treatment of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 10×
“…have an unsatisfactorily high failure rate; it has been estimated that up to 60% of depressed patients suffer from treatment-resistant depression (TRD) (Fava, 2003; Trivedi et al., 2006), with remission rates declining even further following successive treatment failures (Rush et al., 2006).”
BackgroundInfluentialTargeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 2×
“However, clinical trials to date, which have focused exclusively on the use of P-gp inhibitors in combination with cytotoxic drugs in treatment resistant cancer, have not proven to be successful due to pharmacokinetic and pharmacodynamic limitations (Szakacs et al., 2006; Colabufo et al., 2010).”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Pericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843 · cited 7×
“Importantly, several members of the ABC superfamily are localized at the luminal membrane of human BCECs, namely P-glycoprotein [P-gp; encoded by the multidrug resistance 1 (MDR1/ABCB1) gene], breast cancer resistance protein (BCRP; encoded by ABCG2) and multidrug resistance-associated proteins 4 and 5 (MRP4 and 5; en…”
BackgroundInfluentialThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE
Reese, T. S., & Karnovsky, M. J. (1967) · The Journal of Cell Biology · doi:10.1083/jcb.34.1.207 · Cited by 2,629 · cited 1×
“Tight junctions form between BCECs, resulting in a continuous cellular barrier that prevents the passive diffusion of substances into the brain from the blood via the paracellular route of transport (Reese and Karnovsky, 1967; Brightman and Reese, 1969).”
BackgroundThe HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Replicating genotype–phenotype associations
NCI-NHGRI Working Group on Replication in Association Studies, Chanock, S. J., Manolio, T., Boehnke, M., Boerwinkle, E., Hunter, D. J., Thomas, G., Hirschhorn, J. N., Abecasis, G., Altshuler, D., et al. (2007) · Nature · doi:10.1038/447655a · Cited by 1,352 · cited 2×
“drawing accurate conclusions from genetic epidemiology studies (Chanock et al., 2007; Kraft, 2008).”
BackgroundCytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 2×
“, 2009) and immune activation, with correspondingly increased circulating cytokine levels, has been widely reported in depressed patients (Schiepers et al., 2005; Dinan, 2009).”
BackgroundThe ascent of mouse: advances in modelling human depression and anxiety
Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198 · cited 2×
“forced swim test and tail suspension test) (Cryan and Holmes, 2005).”
BackgroundSelf-citationStrategies to advance translational research into brain barriers
Neuwelt, E., Abbott, N. J., Abrey, L., Banks, W. A., Blakley, B., Davis, T., Engelhardt, B., Grammas, P., Nedergaard, M., Nutt, J., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70326-5 · Cited by 474
Brain endothelial cells and the glio-vascular complex
Wolburg, H., Noell, S., Mack, A., Wolburg-Buchholz, K., & Fallier-Becker, P. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0658-9 · Cited by 438
Pathophysiology of hypercortisolism in depression
Carroll, B. J., Cassidy, F., Naftolowitz, D., Tatham, N. E., Wilson, W. H., Iranmanesh, A., Liu, P. Y., & Veldhuis, J. D. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.00967.x · Cited by 317 · cited 10×
“These glucocorticoid hormones, including cortisol, the main glucocorticoid in humans, inhibit the release of CRH and ACTH from the hypothalamus and pituitary gland respectively, thus exerting negative feedback control on the system.”
BackgroundInfluentialBauer, B., Hartz, A. M. S., & Miller, D. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029512 · Cited by 275
Pariante, C. M., Makoff, A., Lovestone, S., Feroli, S., Heyden, A., Miller, A. H., & Kerwin, R. W. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704368 · Cited by 159 · cited 2×
“Co-incubation with the P-gp inhibitor verapamil attenuated or reduced the glucocorticoid-enhancing effect of the antidepressants clomipramine and fluoxetine (Pariante et al., 2001; 2003a,b), thus indicating that antidepressant-mediated P-gp inhibition may be the underlying mechanism at play.”
BackgroundSteroid-Independent Translocation of the Glucocorticoid Receptor by the Antidepressant Desipramine
Pariante, C. M., Pearce, B. D., Pisell, T. L., Owens, M. J., & Miller, A. H. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.4.571 · Cited by 156
Pariante, C. M., Kim, R. B., Makoff, A., & Kerwin, R. W. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705357 · Cited by 89 · cited 4×
“Furthermore, there is also evidence of neuronal P-gp expression in rats (Pariante et al., 2003a; Karssen et al., 2004; Volk et al., 2004; Lazarowski et al., 2007).”
BackgroundInfluentialPariante, C. M., Hye, A., Williamson, R., Makoff, A., Lovestone, S., & Kerwin, R. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300195 · Cited by 70 · cited 4×
“Furthermore, there is also evidence of neuronal P-gp expression in rats (Pariante et al., 2003a; Karssen et al., 2004; Volk et al., 2004; Lazarowski et al., 2007).”
BackgroundInfluentialPariante, C. M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.067 · Cited by 58
Yau, J. L. W., Noble, J., Thomas, S., Kerwin, R., Morgan, P. E., Lightman, S., Seckl, J. R., & Pariante, C. M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301389 · Cited by 46
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738
“ABC transporters are largely known to actively prevent accumulation of drugs and other agents in the brain [12, 18, 19].”
BackgroundSelf-citationPark, T.-E., Mustafaoglu, N., Herland, A., Hasselkus, R., Mannix, R., FitzGerald, E. A., Prantil-Baun, R., Watters, A., Henry, O., Benz, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10588-0 · Cited by 594
Intranasal drug delivery: An efficient and non-invasive route for systemic administration
Grassin-Delyle, S., Buenestado, A., Naline, E., Faisy, C., Blouquit-Laye, S., Couderc, L.-J., Le Guen, M., Fischler, M., & Devillier, P. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.003 · Cited by 398
Metadata
- Authors
- O'Brien, F. E., Dinan, T. G., Griffin, B. T., & Cryan, J. F.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-12-16
- Volume
- 165
- Issue
- 2
- Pages
- 289-312
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1501777540
- Cited by
- 215
- References
- 28
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.